[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,750,934
  • Shares Outstanding, K 88,610
  • Annual Sales, $ 172,350 K
  • Annual Income, $ -285,420 K
  • EBIT $ -224 M
  • EBITDA $ -234 M
  • 60-Month Beta 0.40
  • Price/Sales 10.24
  • Price/Cash Flow N/A
  • Price/Book 116.90

Options Overview Details

View History
  • Implied Volatility 59.85% (-0.32%)
  • Historical Volatility 52.66%
  • IV Percentile 4%
  • IV Rank 13.44%
  • IV High 150.01% on 10/16/25
  • IV Low 45.85% on 03/12/26
  • Expected Move (DTE 14) 1.11 (5.53%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 98
  • Volume Avg (30-Day) 310
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 15,879
  • Open Int (30-Day) 15,281
  • Expected Range 18.89 to 21.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 6
  • High Estimate $-0.35
  • Low Estimate $-0.52
  • Prior Year $-0.70
  • Growth Rate Est. (year over year) +32.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.20 +17.17%
on 08/05/26
25.24 -20.16%
on 07/08/26
-3.09 (-13.29%)
since 07/07/26
3-Month
16.66 +20.96%
on 06/08/26
25.24 -20.16%
on 07/08/26
-0.39 (-1.89%)
since 05/07/26
52-Week
12.10 +66.55%
on 08/11/25
25.59 -21.25%
on 03/25/26
+7.43 (+58.43%)
since 08/07/25

Most Recent Stories

More News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1,...

SNDX : 20.17 (+2.07%)
Syndax: Q2 Earnings Snapshot

Syndax: Q2 Earnings Snapshot

SNDX : 20.17 (+2.07%)
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™...

SNDX : 20.17 (+2.07%)
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 20.17 (+2.07%)
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

–   Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – –   SNDX-62122, a next-generation...

SNDX : 20.17 (+2.07%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1,...

SNDX : 20.17 (+2.07%)
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib...

SNDX : 20.17 (+2.07%)
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across...

SNDX : 20.17 (+2.07%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1,...

SNDX : 20.17 (+2.07%)
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered...

SNDX : 20.17 (+2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 21.32
2nd Resistance Point 20.85
1st Resistance Point 20.31
Last Price 20.17
1st Support Level 19.30
2nd Support Level 18.83
3rd Support Level 18.29

See More

52-Week High 25.59
Fibonacci 61.8% 20.44
Last Price 20.17
Fibonacci 50% 18.85
Fibonacci 38.2% 17.25
52-Week Low 12.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.